A one-year course of abatacept can delay rheumatoid arthritis by as much as four years, even after treatment ends, according to new research from King's College London published in The Lancet Rheumatology.
The finding offers the first concrete evidence that early intervention in high-risk patients can substantially postpone the onset of a disease that affects roughly half a million people in the UK. Rheumatoid arthritis is an autoimmune condition in which the body's immune system attacks the joints, causing pain, swelling, fatigue, and progressive damage that can lead to disability.
The study tracked 213 participants from the UK and the Netherlands for four to eight years, making it one of the longest follow-up examinations ever conducted in people at risk of developing the disease. The trial built on earlier work King's researchers reported in 2024, extending observations to capture the long-term trajectory of patients who received abatacept versus placebo.
No currently approved therapy exists to prevent rheumatoid arthritis in people known to be at high risk. Many patients experience challenges before diagnosis, leaving the workforce early and facing financial strain. The new results suggest a path forward: intervene before symptoms emerge to reshape the disease's timeline.
Researchers identified the highest-risk participants through blood tests that detected autoantibodies associated with rheumatoid arthritis. Those individuals benefited most from early treatment, developing the disease years later than those who received placebo. During the months before the disease appeared, patients on abatacept reported improvements in joint pain and fatigue along with better overall well-being compared to the placebo group.
Once treatment stopped, however, symptom relief declined. Both groups eventually reported similar levels of joint pain and fatigue, suggesting that ongoing immune modulation would be necessary to maintain day-to-day benefits. The disease-delaying effect persisted long after the medication ended, but the symptomatic improvements did not.
Professor Andrew Cope, lead author and Professor of Rheumatology at King's College London, said the findings reinforce the value of early intervention. "This could reduce how long people live with symptoms and complications, drastically improving their quality of life," he noted, emphasizing that the approach is safe and that serious adverse events occurred at similar rates in both treatment and placebo groups.
Researchers observed no new safety concerns linked to abatacept during the extended follow-up period. The drug did not prevent rheumatoid arthritis entirely but meaningfully altered its course, potentially giving patients years of additional time before facing the full burden of the disease.
The results reinforce the case for targeting autoimmune diseases before they fully emerge and open the door to further research into preventive strategies across other autoimmune conditions.
Author Jessica Williams: "Early treatment to delay a chronic disease by years is a genuine breakthrough, but the loss of symptom relief after stopping the drug is a real constraint on this approach that deserves serious attention."
Comments